CytoDyn Q1 Loss Widens to $19.9M; Going Concern Warning Reiterated
CYDY is trading near its 52-week low of $0.183 (9.3% above the low).
Summary
CytoDyn reported a $19.9M quarterly loss, reiterated its going concern warning, and disclosed progress on settling multiple shareholder lawsuits.
Key Events · Earnings and Guidance · CYDY
-
Q1 Net Loss Triples to $19.9M
Net loss for the three months ended August 31, 2026 was $19.9 million, up from $5.5 million in the prior-year quarter, driven primarily by a $12.3 million non-cash loss on note extinguishment and $3.9 million in private placement issuance costs.
-
Going Concern Warning Reiterated
The company's accumulated deficit reached $950.4 million, and management again stated substantial doubt about CytoDyn's ability to continue as a going concern without additional capital.
-
Cash Position at $16.4M
Cash and cash equivalents totaled $16.4 million as of August 31, 2026, against $49.7 million in short-term liabilities, leaving limited runway without further financing.
-
Derivative Lawsuits Settlement in Principle
On September 30, 2026, the parties notified courts of an agreement in principle to settle the pending shareholder derivative lawsuits, subject to documentation and court approval.
Analysis · CYDY · Life Sciences
The quarterly loss more than tripled year-over-year to $19.9 million, driven by a $12.3 million non-cash loss on note extinguishment tied to the August private placement and $3.9 million in issuance costs. Management reiterated the going concern warning with a $950.4 million accumulated deficit and only $16.4 million in cash against $49.7 million in short-term liabilities. The filing also reveals a settlement in principle for the shareholder derivative lawsuits and a November 2, 2026 hearing for final approval of the securities class action settlement.
How filings like this one have moved
In the 30 days to Oct 14, 2026, 36.3% of the 974 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.60%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, CYDY was trading at $0.20 on OTC in the Life Sciences sector, with a market capitalization of approximately $292.3M. The 52-week trading range was $0.18 to $0.40. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.